These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22928999)

  • 1. AbobotulinumtoxinA for reduction of glabellar lines in patients with skin of color: post hoc analysis of pooled clinical trial data.
    Taylor SC; Callender VD; Albright CD; Coleman J; Axford-Gatley RA; Lin X
    Dermatol Surg; 2012 Nov; 38(11):1804-11. PubMed ID: 22928999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Rubin M; Dover J; Maas C; Nestor M
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Baumann L; Brandt FS; Kane MA; Donofrio LM
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A.
    Lawrence I; Moy R
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S66-71. PubMed ID: 19945007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Cohen JL; Schlessinger J; Cox SE; Lin X;
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S43-9. PubMed ID: 19945004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A.
    Schlessinger J; Monheit G; Kane MA; Mendelsohn N
    Dermatol Surg; 2011 Oct; 37(10):1434-42. PubMed ID: 21745254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PrabotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines in Adult Patients With Skin of Color: Post Hoc Analyses of the US Phase III Clinical Study Data.
    Taylor SC; Grimes PE; Joseph JH; Jonker A; Avelar RL
    Dermatol Surg; 2021 Apr; 47(4):516-521. PubMed ID: 33165078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines.
    Monheit GD; Baumann L; Maas C; Rand R; Down R
    Dermatol Surg; 2020 Jan; 46(1):61-69. PubMed ID: 31356432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide.
    Matarasso A; Shafer D
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S72-9. PubMed ID: 19945008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type A for facial wrinkles.
    Camargo CP; Xia J; Costa CS; Gemperli R; Tatini MD; Bulsara MK; Riera R
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD011301. PubMed ID: 34224576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects.
    Harii K; Kawashima M
    Aesthetic Plast Surg; 2008 Sep; 32(5):724-30. PubMed ID: 18663516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
    Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q
    Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects.
    Kawashima M; Harii K
    Int J Dermatol; 2009 Jul; 48(7):768-76. PubMed ID: 19490208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Assessment of 2 Licensed AbobotulinumtoxinA Injection Volumes for the Treatment of Glabellar Lines.
    Kaufman J; Cohen JL; Peredo MI; Jonas B; Down R; Nogueira A
    Dermatol Surg; 2019 Oct; 45(10):1274-1284. PubMed ID: 30893159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2).
    Bertucci V; Solish N; Kaufman-Janette J; Yoelin S; Shamban A; Schlessinger J; Snyder D; Gallagher C; Liu Y; Shears G; Rubio RG
    J Am Acad Dermatol; 2020 Apr; 82(4):838-845. PubMed ID: 31791824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
    Dessy LA; Fallico N; Mazzocchi M; Scuderi N
    Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety of abobotulinumtoxinA for the treatment of glabellar lines: results from a 36-month, multicenter, open-label extension study.
    Schlessinger J; Dover JS; Joseph J; Monheit G; Nelson DB; Albright CD; Axford-Gatley RA; Cohen JL;
    Dermatol Surg; 2014 Feb; 40(2):176-83. PubMed ID: 24372978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program.
    Cohen JL; Green LJ; Beer KR; Liu Y; Gallagher CJ
    Dermatol Surg; 2021 Apr; 47(4):511-515. PubMed ID: 33587381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment of Upper Facial Lines.
    Hexsel D; Cartier H; Hedén P; Delmar H; Bergentz P; Camozzato F; Siega C; Skoglund C; Edwartz C; Rees D; Kestemont P
    Dermatol Surg; 2018 Dec; 44(12):1555-1564. PubMed ID: 30204739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subject satisfaction and psychological well-being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines.
    Dayan S; Joseph J; Moradi A; Lorenc ZP; Coleman K; Ablon G; Kaufman-Janette J; Cox SE; Campbell A; Munavalli G; Prygova I
    J Cosmet Dermatol; 2022 Jun; 21(6):2407-2416. PubMed ID: 35266281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.